格列本脲用于动脉瘤性蛛网膜下腔出血(GASH):一项随机对照试验的研究方案
本研究为随机对照试验方案,计划纳入约80例动脉瘤性蛛网膜下腔出血患者,随机分为格列本脲5 mg每日口服21天组与安慰剂对照组,主要结局为6个月时改良Rankin量表(mRS)评分(0-2分为良好,3-6分为不良),次要结局包括6个月时认知状态、死亡、迟发性脑缺血及研究药物相关严重不良事件。
要点
- 格列本脲组每日口服5 mg,持续21天,对照组为安慰剂。
- 主要结局为6个月时mRS评分,分为良好(0-2分)与不良(3-6分)。
- 次要结局包括6个月时认知状态、死亡、迟发性脑缺血及严重不良事件。
核心结论
- 基于实验模型数据,计划开展临床试验以确立格列本脲作为动脉瘤性蛛网膜下腔出血辅助治疗的证据。
研究设计与样本
- 随机对照试验方案,计划纳入约80例符合纳入标准的动脉瘤性蛛网膜下腔出血患者。
- 纳入标准:影像学确诊动脉瘤性蛛网膜下腔出血、年龄18-70岁、发病至入组小于96小时。
- 随机分为两组,一组每日口服格列本脲5 mg持续21天,另一组为安慰剂对照。
主要发现
- 原文为研究方案,未报告试验结果。
关键数值与推荐
- 主要结局为6个月时改良Rankin量表(mRS)评分,分为良好(mRS 0-2)或不良(mRS 3-6)。
- 次要结局为6个月时通过心理测试(简短健康调查问卷和蒙特利尔认知评估)评估的晚期认知状态,以及6个月时死亡、迟发性脑缺血和研究药物相关严重不良事件的发生。
临床怎么用
- 原文未据此给出推荐。
局限性
- 试验注册为回顾性注册,于2018年6月26日注册。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent findings on the benefits of glibenclamide as a neuroprotective drug have started a new era for prospective studies on sulfonylureas. The effect of glibenclamide blocking the Sur1-Trpm4 channel was examined in models of subarachnoid hemorrhage and stroke, with findings of significantly reduced tight-junction abnormalities, resulting in less edema formation and considerably reduced transsynaptic apoptosis of hippocampal neurons and significantly ameliorated impairments in spatial learning. Based on these data, we plan a clinical trial to establish evidence of glibenclamide as an adjunct treatment in aneurysmal subarachnoid hemorrhage. METHODS: An estimated 80 patients meeting the inclusion criteria of radiological confirmatory evidence of an aneurysmal subarachnoid hemorrhage, age 18-70 years, and presentation of less than 96 h from the ictus will be allocated randomly into two groups, one receiving 5 mg daily oral intake of glibenclamide for 21 days and another control group receiving a placebo. The study's primary outcome is the modified Rankin scale (mRS) after 6 months, as favorable (mRS 0-2) or unfavorable (mRS 3-6). The secondary outcomes will be late cognitive status, assessed after 6 months by psychological tests (the Short Form Health Survey Questionnaire and the Montreal Cognitive Assessment), as well as death at 6 months, delayed cerebral ischemia and occurrence of serious adverse events due to study medication. DISCUSSION: There is a growing interest in the scientific community regarding glibenclamide in brain edema and traumatic brain injury, but with very little of this interest targeting spontaneous brain hemorrhage, especially aneurism rupture. Positive outcomes are expected for the treatment patients, especially in language and memory preservation, as has been shown in experimental models. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03569540 . Retrospectively registered on 26 June 2018.
引用
- da Costa BBS, Windlin IC, Koterba E, et al. Glibenclamide in aneurysmatic subarachnoid hemorrhage (GASH): study protocol for a randomized controlled trial. Trials. 2019. PMID: 31288831. doi:10.1186/s13063-019-3517-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。